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Abstract
Introduction Dehydroepiandrosterone (DHEA), an adrenal 17-
ketosteroid, is a precursor of testosterone and 17β-estradiol.
Studies have shown that DHEA inhibits carcinogenesis in
mammary gland and prostate as well as other organs, a process
that is not hormone dependent. Little is known about the
molecular mechanisms of DHEA-mediated inhibition of the
neoplastic process. Here we examine whether DHEA and its
analog DHEA 8354 can suppress the progression of
hyperplastic and premalignant (carcinoma in situ) lesions in
mammary gland toward malignant tumors and the cellular
mechanisms involved.
Methods Rats were treated with N-nitroso-N-methylurea and
allowed to develop mammary hyperplastic and premalignant
lesions with a maximum frequency 6 weeks after carcinogen
administration. The animals were then given DHEA or DHEA
8354 in the diet at 125 or 1,000 mg/kg diet for 6 weeks. The
effect of these agents on induction of apoptosis, senescence,
cell proliferation, tumor burden and various effectors of cellular
signaling were determined.
Results Both agents induced a dose-dependent decrease in
tumor multiplicity and in tumor burden. In addition they induced
a senescent phenotype in tumor cells, inhibited cell proliferation
and increased the number of apoptotic cells. The DHEA-
induced cellular effects were associated with increased
expression of p16 and p21, but not p53 expression, implicating
a p53-independent mechanism in their action.
Conclusion We provide evidence that DHEA and DHEA 8354
can suppress mammary carcinogenesis by altering various
cellular functions, inducing cellular senescence, in tumor cells
with the potential involvement of p16 and p21 in mediating
these effects.
Introduction
Dehydroepiandrosterone (DHEA) is a 17-ketosteroid that is
produced at high levels in the adrenals of primates and is the
chief precursor of androstenedione, which itself is readily con-
verted into testosterone and 17β-estradiol at the tissue level
[1]. Epidemiological data have shown that premenopausal
women with high levels of DHEA in the serum develop less
breast carcinomas than those with low levels of DHEA [2]. In
postmenopausal women DHEA has been hypothesized to
contribute to the increased incidence of breast cancer [3].
Studies on animal model systems revealed that DHEA is a
powerful inhibitor of mammary, prostate, skin, lung, liver, and
thyroid carcinogenesis [4-7]. DHEA and its fluorinated ana-
logue, DHEA 8354, given after carcinogen administration,
inhibited mammary carcinogenesis in rats in a dose-depend-
ent manner [6,7]. DHEA combined with 4-(Hydroxyphenyl)ret-
inamide (4-HPR) further decreased the incidence and
frequency of mammary tumors in an N-nitroso-N-methylurea
(MNU) carcinogenesis model [4]. Tamoxifen (0.08 mg/kg diet)
combined with low-dose DHEA (400 mg/kg diet) further
decreased the incidence and multiplicity of mammary tumors
[6]. DHEA also decreased the incidence of mammary tumorsR1132
BrdU = bromodeoxyuridine; DHEA = dehydroepiandrosterone; ER = estrogen receptor; ICH = immunocytochemical assay; MNU = N-nitroso-N-
methylurea; SA-β-Gal = senescence-associated β-galactosidase.
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R1133in rats injected with dimethylbenz(a)anthracene (DMBA) into
mammary gland parenchyma and continuously stimulated with
prolactin [8]. Studies with C3(1)/SV40 Tag mice, which can
spontaneously develop estrogen receptor (ER)-negative mam-
mary and prostate tumors, have shown that DHEA at 4,000
mg/kg diet given between the 7 th and 19 th weeks of age,
decreased the incidence of mammary tumors by 30% and
tumor multiplicity by about 50% [9]. Furthermore, in both
DHEA-treated C3(1)/SV40 Tag mice and DHEA-treated rats
the circulating estradiol levels were increased, suggesting the
involvement of a tumor suppressor mechanism that is not
directly related to the ER signaling. DHEA was also effective
in inhibiting the growth of ZR-75-1 ER-positive breast cancer
cells transplanted into nude mice [10]. In most of these stud-
ies, DHEA was given in the diet 1 week before and/or contin-
uously after carcinogen administration, until the animals were
killed [4-6]. However, with this approach the limited number of
tumors that occur in DHEA-treated animals are apparently
resistant to DHEA and therefore the biomarkers that would be
identified might not reflect the preventive and antitumor poten-
tial of DHEA in the course of tumor development. Further, the
molecular mechanism of action of DHEA remains poorly
defined.
Here we have examined the effect of DHEA and its analog
DHEA 8354, initiated 6 weeks after carcinogen administra-
tion, when hyperplastic and premalignant lesions occur in the
mammary gland, on the following: first, the incidence, multiplic-
ity and weight (burden) of mammary tumors; second, the pro-
liferative activity of tumor cells; third, apoptosis; fourth, cellular
senescence; fifth, cell cycle distribution; and sixth, the expres-
sion of p53, p21, and p16. To identify senescent cells in mam-
mary tissues and tumors, a panel of methods was employed,
including senescence-associated β-galactosidase (SA-β-Gal)
staining [11], continuous labeling with bromodeoxyuridine
(BrdU) [12], analysis of 90° light scatter by flow cytometry, and
cytomorphological criteria [13]. Because p53, p21, and/or
p16 genes are key mediators for the initiation and mainte-
nance of cellular senescence and apoptosis [14-17], their role
in such mechanisms was investigated. It has been recently
observed that p16INK4A is overexpressed in senescent cells,
suggesting that it might be upregulated in mammary tumors
treated with DHEA [18]. We provide comprehensive evidence
of a correlation between the inhibitory effects of DHEA on
mammary carcinogenesis, induction of cellular senescence,
inhibition of cell proliferation, induction of apoptosis and the
expression of p21 and p16INK4A.
Materials and methods
Animals
Female, virgin Sprague-Dawley (Hsp: (SD/BR)) rats were
obtained from Harlan Sprague-Dawley (Indianapolis, IN, USA)
at 35 days of age; after 1 week of quarantine they were rand-
omized by weight and injected with carcinogen. Beginning 3
weeks after carcinogen administration, the animals were pal-
pated weekly to monitor tumor appearance in the mammary
gland. The animals were fed with 4% Purina diet chow ad libi-
tum and had free access to water. Rats were weighed weekly
and checked daily for any sign of toxicity.
Chemical carcinogen
MNU was obtained from Ash Stevens Inc. (Detroit, MI, USA),
dissolved in sterile acidified saline (pH 5.0), and injected intra-
peritoneally (50 mg/kg body weight) when the animals were
50 days old. Control animals at the same age received sterile
saline only.
DHEA and DHEA 8354
DHEA was obtained from Sigma Chemical Co. (St Louis, MO,
USA). AHEA 8354 was supplied by the NCI repository
(Bethesda, MD, USA). Both agents were mixed in AIN-76A
purified mice/rat diet (Teklad, Madison, WI, USA) to achieve a
concentration of 125 or 1,000 mg/kg diet. Both agents were
given for 6 weeks, starting 6 weeks after the administration of
carcinogen [19].
Mammary tumors
The growth of mammary tumors was monitored by measuring
their length (L), width (W), and thickness (T). Tumor volume
(VT) was calculated from the formula VT = LWT/2. Animals
were killed by CO2 asphyxiation; the tumors were excised,
weighed, and cut into halves. One half was fixed in 10% neu-
tral formalin for histomorphology, BrdU, and apoptosis assay;
the other half was frozen in liquid nitrogen and stored at -80°C
for the assessment of senescence-like cells by SA-β-Gal stain-
ing, for the assessment of cell cycle distribution by flow cytom-
etry, and for western blotting.
Cell proliferation
Two sets of experiments were performed. In the first, animals
were injected intraperitoneally with BrdU (50 mg/kg body
weight; Sigma) 2 hours before being killed and the percentage
of BrdU-labeled tumor cells was examined. In the second
experiment, animals with palpable mammary tumors were con-
tinuously labeled with BrdU (7 days) by means of osmotic
pumps (Anza Co., Palo Alto, CA, USA) implanted subcutane-
ously. The BrdU-labeled cells in both studies were detected by
an anti-BrdU monoclonal antibody (Becton Dickinson, Palo
Alto, CA, USA) and an ABC kit (Vector, Burlingame, CA,
USA), as described previously [20].
Apoptosis
Apoptotic cells were identified on parallel tissue sections by
TUNEL (TdT-mediated dUTP nick end labelling) assay, as rec-
ommended in the ApopTag in situ hybridization detection kit
(Oncor Co., Gaithersburg, MD, USA).
Cell cycle arrest
Frozen tumor samples (100 to 200 mg) were disintegrated
mechanically and enzymatically to generate a cell suspension
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pidium iodide (50 µg/ml) and the DNA amount in the cells and
the cell cycle distribution were analyzed with a FACS Coulter
counter (EPICS Elite 5, Coulter Co., Miami, FL, USA).
Identification of senescent cells in mammary tumors
The SA-β-Gal activity assay was employed for the identifica-
tion of senescent cells in mammary tissues and tumors [11].
Frozen sections (5 to 7 µm thick) from control animals and
sections of tumors from animals treated with DHEA and DHEA
8354 were fixed in 3.0% formaldehyde for 5 minutes, washed
in phosphate-buffered saline and stained in X-Gal (5-bromo-4-
chloro-3-indolyl-β-D-galactoside; Sigma) solution at pH 6.0 for
24 hours at 37°C, following our protocol described previously
[12].
Expression of p53, p21, and p16
The expression of these genes was assessed by western blot-
ting and immunocytochemical staining (ICH). For western
blotting, frozen tumor tissue (about 100 mg) was disintegrated
with a Sonifer Cell Disruptor in lysis buffer containing a cock-
tail of protease inhibitors (Roche Biochemicals); 50 to 100 µg
of the isolated protein was separated by electrophoresis in a
10 to 20% Tris-glycine gel and transblotted to Immobilon-P
membranes (Millipore, Bedford, MA, USA). Blots were probed
with primary antibody and corresponding secondary antibody.
Antibodies against p53 and p16 were purchased from Santa
Cruz Biotech Inc. (Santa Cruz, CA, USA), and antibodies
against p21 were obtained from R&D Systems Inc., Minneap-
olis, MN.
For ICH, formalin-fixed paraffin-embedded tissue samples
were used. The same antibodies that were employed for west-
ern blotting were also used for ICH. ABC kit and 3,3'-Diami-
nobenzidine (Sigma) staining were used to identify cells
expressing the corresponding antigens. The percentage of
cells positive for p16 or p21 was calculated after counting
more than 1,000 cells. For quantitative analysis of cells stained
with p21 and p16, we first assessed the percentage of cell
nuclei positively stained for the above antigens and scored the
samples from 0 to 3 as follows: 0, 0 to 5%; 1, 6 to 20%, 2, 21
to 50%; 3, more than 50%. Then we assessed the intensity of
staining by using the same 0 to 3 grading system: 0, none
(similar to background staining); 1, weak; 2, moderate; 3,
strong. The data from each score from each tumor were multi-
plied and the result was used to assess the values for each
group. Two pathologists (AS and KC) independently evalu-
ated the samples and the difference in scores was in the range
0 to 20%. p16 and p21 values were generated by employing
a semi-quantitative approach (0 to 3) for positively stained
cells multiplied by the intensity of staining (0 to 3).
Figure 1
DHEA and DHEA8354 suppress the growth of mammary tumors. (a) Growth curves of mammary tumors in control animals. (b, c) Growth curves of 
mammary tumors in animals treated with dehydroepiandrosterone (DHEA) (b) or DHEA 8354 (c) (1,000 mg/kg in diet). In 50% of DHEA-treated 
tumors a net decrease in growth potential over control was observed, whereas with DHEA 8354 some animals showed a decrease in growth poten-
tial. Each curve represents an individual tumor.
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Comparisons of tumor incidence curves for treated and con-
trol animals were made with a life table analysis and the log-
rank test. Tumor multiplicity data were compared by using
Armitage's test for trend in proportion. Body and tumor weight
data were compared with the two-tailed Fisher t test by using
analysis of variance [22].
Results
DHEA and DHEA 8654 suppress the progression phase 
of mammary carcinogenesis
To examine the effects of DHEA and DHEA 8354 on the pro-
gression of these lesions towards malignant tumors, both
agents were added to the diet starting 6 weeks after the
administration of carcinogen. The high doses of DHEA and
DHEA 8354 only decreased the growth potential in some
mammary tumors (Fig. 1). DHEA and DHEA 8354 given for 6
weeks at low (125 mg/kg diet) or high (1,000 mg/kg diet)
dose did not affect the animals' body weight or the incidence
of tumors but decreased tumor multiplicity (Table 1): from 4
tumors per animal in the control group to 3.2 and 2.3 in the
low-dose and high-dose DHEA groups (p < 0.05), respec-
tively. DHEA 8354 was less effective: the decrease in tumor
multiplicity was only 15% at the high dose. The high doses of
both agents also suppressed the tumor burden, from 5.7 g per
animal in control animals to 2.3 g (p < 0.01) and 2.6 g (p <
0.01) per animal in animals treated with DHEA and DHEA
8354, respectively. Morphological examination of tumors
revealed that the high doses of DHEA or DHEA 8354 induced
partial disintegration of tumor parenchyma. The low doses
(125 mg/kg diet) were less efficacious and did not affect
tumor morphology.
DHEA and DHEA 8354 decreased cell proliferation and 
induced apoptosis in mammary tumors
The percentage of BrdU-labeled cells was variable between
individual tumors. Some had more than 20% BrdU-labeled
cells (Fig. 2a), whereas others had less than 5% labeled cells.
However, the high dose of both agents significantly decreased
BrdU-LI, from 15.6 ± 3.8% (SD) in control animals to 2.2 ±
1.2% in DHEA-treated animals (p < 0.01) and to 5.3 ± 1.8%
in DHEA 8354-treated animals (p < 0.01), respectively (Table
2 and Fig. 2c). The low doses of DHEA and DHEA 8354 were
less efficacious. DHEA and DHEA 8354 also increased apop-
totic cells in mammary tumors. In control tumors apoptotic
cells are rarely observed. However, the percentage of apop-
totic cells increased from 0.7 ± 0.4% in control animals to 3.2
± 1.0% in DHEA-treated animals and to 1.5 ± 0.5% in DHEA
8354-treated animals. Low doses of either agent were less
efficacious and did not significantly increase apoptotic cells
(Table 2).
DHEA and DHEA 8354 induced cellular senescence in 
mammary tumors
The cells that developed senescent phenotype were identified
by SA-β-Gal staining. In control animals, SA-β-Gal-stained
cells were few in mammary tumors (0.4 ± 0.2%) and were
localized predominantly in the non-proliferating tumor areas,
whereas in the animals treated with DHEA SA-β-Gal cells
increased preferentially in normal lobular structures (Fig. 2d)
and in tumors. Overall, there were tumors with very few SA-β-
Gal-stained cells (Fig. 2d) and tumors with a relatively large
number of senescent cells (Fig. 2e,f). Statistically, SA-β-Gal
cells increased from 0.4 ± 0.2% in control tumors to 1.9 ±
1.8% (p < 0.01) and to 3.3 ± 2.0% (p < 0.001) in the animals
treated with low and high doses of DHEA, respectively (Table
2). As shown in Fig. 2b, after 7 days of continual BrdU infusion
almost all tumor cells were labeled with BrdU except for a few
cells, which could be considered to be in replicative senes-
cence (Fig. 2b).
DHEA and DHEA 8354 arrest tumor cells in the G1/G0 
phase of the cell cycle
In control tumors (n = 10), the percentages of cells in the G0/
G1 and S phases were 92.3 ± 0.8% and 5.4 ± 2.2%, respec-
tively, whereas in animals treated with DHEA or DHEA 8354
the S phase decreased to 1.8 ± 0.8% (p < 0.001) and 2.1 ±
1.0% (p < 0.001), respectively(Table 3). These results are in
accord with our cell proliferation data. The decrease in S
phase concomitant with an increase in G1/G0 phase sug-
gests that DHEA and DHEA 8354 arrested the cells in the
G1/G0 phase of the cycle (Fig. 3a). Individual histograms also
Table 1
Effects of dehydroepiandrosterone (DHEA) and DHEA 8354 on mammary tumor development
Treatment Dose (mg/kg diet) No. of animals Weight of animals (g) Tumor incidence (%) Tumor multiplicity Tumor (weight) burden (g)
Control 0 20 234 93.3 4.0 5.7
DHEA 125 29 231 96.7 3.2a 3.7b
1,000 30 218 76.7 2.3a 2.3b
DHEA 8354 125 30 227 87.6 3.6 4.7
1,000 29 222 100.0 3.4a 2.6b
aSignificant difference for the frequency of tumors, DHEA (p < 0.01 and p < 0.001) and DHEA 8354 (p < 0.05). bSignificant difference for tumor 
weight/g (p < 0.01 and p < 0.01, DHEA and DHEA 8354, respectively) over the corresponding control (MNU-treated) groups.
Available online http://breast-cancer-research.com/content/7/6/R1132
R1136showed cells with DNA values below those of the G1/G0
peak (Fig. 3b-d), which represent the apoptotic cells. A small
subset of cells were identified in the hyperdiploid and hyper-
tetraploid region of the histograms, which probably represent
some of the senescent cells (Fig. 3c,d).
Mechanism of cellular senescence induced by DHEA and 
DHEA 8354
The expression of p53, p21, and p16 was examined by ICH
(Fig. 3 and Table 4) and western blotting (Fig. 4). The
differences in the levels of p21-stained cells in control animals
over those treated with DHEA were not significant (p < 0.2),
whereas those for p16 were highly significant (p < 0.01). The
level of p53 remained unaltered in control and DHEA-treated
animals; they are therefore not included in Table 4. Figure 2h
shows a mammary tumor from a control animal with most cells
positively stained for p21; in contrast, p16-stained cells of a
mammary tumor from a control animal are shown in Fig. 2i.
However, in the animals treated with the DHEA diet we could
Table 2
Effects of DHEA and DHEA 8354 on SA-β-Gal cells, BrdU-labeled cells and apoptosis
Treatment Dose (mg/kg diet) No. of tumorsa SA-β-Gal cells (%) BrdU-labelled cells (%) Apoptosis (%)
Control 0 10 0.4 ± 0.2 15.6 ± 4.8 0.7 ± 0.4
DHEA 125 9 1.9 ± 1.8b 9.9 ± 4.2c 1.6 ± 0.4d
1,000 15 3.3 ± 2.0b 2.2 ± 1.2c 3.2 ± 2.0d
DHEA 8354 125 8 0.7 ± 0.4 13.5 ± 4.4 1.1 ± 0.4
1,000 10 2.8 ± 1.0b 5.3 ± 1.8c 1.5 ± 0.5d
aOne tumor per animal was examined once; b,c,dthe differences in values between treated and control tumors are significant (p < 0.05; Student's t 
test). BrdU, bromodeoxyuridine; DHEA, dehydroepiandrosterone; SA-β-Gal, senescence-associated β-galactosidase (mean ± SD%) values.
Figure 2
DHEA and DHEA8354 induce cellular senescence, inhibit cell proliferation and increase apoptosis in mammary tumors. (a-c) Cell proliferation in 
control mammary tumors (a,b) and in tumors treated with dehydroepiandrosterone (DHEA) (c). DHEA significantly decreased the proportion of bro-
modeoxyuridine-labeled cells (c). The slide was counterstained with hematoxylin; original magnification × 100. (d-f) DHEA-induced cellular senes-
cence (SA-β-Gal-stained cells) in normal lobular cells (d, arrows) and in mammary tumors (e and f, arrows). (g,h) p21 and p16 were expressed in 
most mammary tumor cells. DHEA also induced tumor disintegration and in these areas p16 (arrows) was preferentially detected in tumor areas 
where SA-β-Gal-stained cells were also identified.
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morphological structures in which SA-β-Gal-stained cells
were also identified (compare Fig. 2f with Fig. 2i).
For western blotting, tumors were selected that had high pro-
portions (more than 3.0%) of SA-β-Gal-stained cells. It seems
that DHEA given for 6 weeks induced the expression of p16
and p21, but not that of p53, suggesting a p53-independent
mechanism of induction of cellular senescence and of cell
growth inhibition (Fig. 5).
Discussion
In a previous study we observed that 5 to 6 weeks after the
administration of MNU (by the injection of 50 mg/kg body
weight) all Sprague-Dawley rats developed multiple hyper-
plastic and premalignant lesions in the mammary gland [23].
The main objective of this study was therefore to examine
whether DHEA and its analog DHEA 8354 could suppress the
progression of hyperplastic and premalignant lesions in the
mammary gland towards malignant tumors and to identify the
cellular mechanisms involved in this process. The progression
phase was considered to be the time between the occurrence
of hyperplastic and premalignant (carcinoma in situ) lesions in
the mammary gland and the development of palpable tumors.
We therefore administered DHEA and DHEA 8354 in the diet,
starting 6 weeks after MNU administration, when most hyper-
plastic and premalignant (carcinoma in situ) mammary lesions
occurred [23]. Both agents were used at doses reported to
show an inhibitory effect on mammary carcinogenesis [6,7].
The decrease in tumor multiplicity brought about by DHEA and
DHEA 8354 is apparently a consequence of inhibition in the
progression of existing hyperplastic and premalignant lesions
as well as a decrease in the occurrence of new lesions. The
decrease in tumor burden is a complex phenomenon involving
the inhibition of cell proliferation and the induction of
apoptosis and of cellular senescence. We previously exam-
ined several preventive agents for their effects on cell prolifer-
ation and apoptosis [19,20]. More recently we included
markers of cellular senescence [12], which have been widely
used in characterizing the senescent phenotype [24]. To
ensure that in control and DHEA-treated mammary tumors
there were non-proliferating cells, animals were implanted
subcutaneously with osmotic pumps that continuously
Figure 3
Effects of DHEA and DHEA8354 on the cell cycle t  l  ycle. (a-c) Cell cycle distribution in MNU-induced mammary tumor of a control animal (a) and in an ani-
mal treated with dehydroepiandrosterone (DHEA) (b,c). Control tumors showed a low level of S-phase cells and a lack of cells with hypodiploid val-
ues of DNA. DHEA treatment induced an increase in apoptotic cells (b, arrow) and a decrease in G2M phase. A cell population is identified with 
DNA values after the G1/G0 peak (c, arrow), suggesting DNA abnormalities typical for senescent cells from another mammary tumor from an animal 
treated with DHEA. (d) DHEA induced both apoptosis and senescence (a small area after the G1/G0 peak (arrow), indicative of senescence.
Table 3
Effects of DHEA and DHEA 8354 on the cell cycle phases (flow cytometry data)
Treatment Dose (mg/kg diet) No. of tumors Phase of the cell cycle
G1/G0 (%) S (%) G2M (%)
MNU - 10 92.3 ± 0.8 5.4 ± 2.2 2.4 ± 1.1
DHEA 1,000 11 95.9 ± 1.8a 1.8 ± 0.8b 2.1 ± 1.5
DHEA 8354 1,000 14 94.8 ± 1.7a 2.1 ± 1.0b 2.3 ± 1.1
a,bSignificant (p < 0.001) differences from control tumors. DHEA, dehydroepiandrosterone; MNU, N-nitroso-N-methylurea (mean ± SD) values.
Available online http://breast-cancer-research.com/content/7/6/R1132
R1138released BrdU and thus specifically labeled proliferating cells
during the S phase of the cell cycle. Because the cell cycle
time of mammary tumors in rats is about 18 hours [26] (Chris-
tov K, Lubet R, Steele V., Grubbs C., unpublished data), a 7-
day delivery of BrdU by means of osmotic pumps would label
all cells passing through at least eight or nine consecutive cell
cycles, whereas cells in terminal proliferative arrest would
remain unlabeled and could be considered senescent [13].
The mechanisms involved in the initiation and maintenance of
cellular senescence in tumor cell systems are poorly under-
stood. Most studies on cell lines indicate that the induction
and overexpression of wild-type p53 (mostly by cytotoxic
agents or irradiation) can cause cell growth arrest, apoptosis,
DNA repair, and/or the eventual development of a senescent
phenotype [13,15]. The primary effector of p53 in cellular
senescence is believed to be the cdk2/4 inhibitor p21, which
by downregulation of E2F prevents the expression of the
genes required for S-phase initiation and DNA replication [25].
However, there is increasing evidence with cell differentiation
agents, as we have shown with retinoids, to suggest that the
p16-pRb (Retinoblastoma protein) pathway is also involved in
cellular senescence [17]. Overexpression of p16 apparently
inhibits cdk4/6 activity and pRb phosphorylation, and thus
suppresses cell cycle progression [14,16]. Our data support
the potential role of p16 in mediating the antitumor effects of
DHEA and DHEA 8354. In contrast, p53 expression was not
affected, as determined by western blotting and ICH (data not
shown). Because the animals in this study were treated with
DHEA and DHEA 8354 for 6 weeks and then tumors were
examined, we cannot exclude the possibility that at early time
points the gene encoding p53, or other genes, might also con-
tribute to the development of cellular senescence in mammary
tumors.
The exact mechanism by which DHEA exerts its chemopreven-
tive and antitumor effects on mammary carcinogenesis is not
known. In animals treated with DHEA an increase in estradiol
circulation level has been observed, suggesting more general
mechanisms of tumor growth inhibition. This has been also
supported by the data from C3(1)/SV40 Tag-transgenic mice,
which spontaneously develop ER-negative mammary tumors
and were also suppressed by DHEA [9]. DHEA has similarly
been found to suppress prostate carcinogenesis in rats [27],
despite the fact that it may increase the levels of testosterone
and dihydrotestosterone [28]. DHEA is also known to activate
peroxisome proliferator-activated receptor (PPAR)-α and
Table 4
Effects of dehydroepiandrosterone on p16 and p21 expression in mammary tumors (immunohistochemical assay)
Group No. of animals p16 P21
Expressiona p Expressiona p
Control 10 3.5 ± 2.2 5.6 ± 1.3
Dehydroepiandrosteroneb 8 6.3 ± 2.2 0.01 6.1 ± 1.2 n.s.
ap16 and p21 values were generated semiquantitatively as described in the Materials and methods section; bdehydroepiandrosterone was given 
at 1,000 mg/kg.
Figure 4
DHEA and DHEA8354 differentially affect p16, p21, and p53 protein expression: Western blot data of control tumors (lanes 1 to 3) and tumor  treated with DHEA (1,000 mg/kg diet) (lanes 4 to 6) as esti-mated by west rn blotting
expression: Western blot data of control tumors (lanes 1 to 3) and 
tumors treated with DHEA (1,000 mg/kg diet) (lanes 4 to 6) as esti-
mated by western blotting. For western blotting, tumors were selected 
with relatively high values of senescence-associated β-galactosidase 
(SA-β-Gal)-labelled cells and low values of bromodeoxyuridine-labeled 
cells.
Figure 5
A hypothetical model of inhibition of mammary carcinogenesis by DHEA
DHEA. Our data indicate that DHEA, by increasing p16 and p21 
expression, may suppress cell proliferation and induce senescence and 
apoptosis. The arrows indicate the changes in the corresponding 
parameters.
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genesis [7].
Our data indicate that DHEA and DHEA 8354 at doses of
1,000 mg/kg diet had the following effects: they decreased
the multiplicity and the weight (burden) of mammary tumors;
they induced cellular senescence; they inhibited cell prolifera-
tion; they arrested the cells in G1/G0 phases of the cell cycle;
they increased apoptotic cell death; and they induced the
expression of p16 and p21 but not that of p53.
On the basis of our results we propose a model of inhibition of
mammary carcinogenesis by DHEA that involves the suppres-
sion of cell proliferation, the induction of senescence in tumor
cells and the induction of apoptosis (Fig. 5); these cellular
events are apparently associated with the upregulation of p16
and p21 but not that of p53, implying a p53-independent
mechanism.
Conclusion
In this study we provide evidence that DHEA and DHEA 8354
suppress the progression phase of mammary carcinogenesis
by inducing cellular senescence, inhibiting cell proliferation
and increasing apoptotic cell death. We also found that
p16INK4A and p21, but not p53, are upregulated in mammary
tumors of animals treated with high doses of DHEA, suggest-
ing a p53-independent mechanism of tumor suppression.
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